685540-79-8Relevant articles and documents
Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC
Singh, Pankaj Kumar,Chaudhari, Dasharath,Jain, Sanyog,Silakari, Om
supporting information, p. 1565 - 1571 (2019/05/15)
Secondary acquired mutant EGFR (L858R-T790M)overexpressed NSCLC forms one of the prevalent form of resistant NSCLC. Another subset of resistant NSCLC includes amplified cMET in mutant EGFR derived tumours. Thus, in continuation to our previous work on the
Discovery of inhibitors of Burkholderia pseudomallei methionine aminopeptidase with antibacterial activity
Wangtrakuldee, Phumvadee,Byrd, Matthew S.,Campos, Cristine G.,Henderson, Michael W.,Zhang, Zheng,Clare, Michael,Masoudi, Ali,Myler, Peter J.,Horn, James R.,Cotter, Peggy A.,Hagen, Timothy J.
supporting information, p. 699 - 703 (2013/09/02)
Evaluation of a series of MetAP inhibitors in an in vitro enzyme activity assay led to the first identification of potent molecules that show significant growth inhibition against Burkholderia pseudomallei. Nitroxoline analogues show excellent inhibition potency in the BpMetAP1 enzyme activity assay with the lowest IC50 of 30 nM and inhibit the growth of B. pseudomallei and B. thailandensis at concentrations ≥31 μM.